Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.05 HKD | +0.22% | +6.47% | +5.98% |
26/04 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | Baiyunshan Pharmaceutical's 2023 Profit Rises 2% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.23 for the 2024 fiscal year.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.98% | 707.52Cr | B- | ||
+31.37% | 59TCr | B | ||
-2.60% | 36TCr | C+ | ||
+20.83% | 33TCr | B- | ||
+5.69% | 29TCr | C+ | ||
+14.83% | 24TCr | B+ | ||
+9.93% | 21TCr | B- | ||
-6.95% | 20TCr | A+ | ||
+10.77% | 17TCr | C+ | ||
+0.10% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 874 Stock
- Ratings Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.